Neomorph

Molecular glue drug discovery

Neomorph is a biotech company targeting protein degradation to eliminate disease-linked and previously labeled 'undruggable' proteins. The team's expertise in protein degradation and molecular glues allows them to develop heterobifunctional molecules that can degrade proteins using a molecular glue mechanism. Neomorph is collaborating with the Center for Protein Degradation at the Dana Farber Cancer Institute, as well as Novo Nordisk to discover and develop drugs for cardiometabolic and rare diseases. They were founded in 2020 with headquarters located in San Diego, CA.